Multiparametric Magnetic Resonance Imaging of the Prostate and Prostate-specific Membrane Positron Emission Tomography Prior to Prostate Biopsy (MP4 Study)

被引:4
|
作者
Woo, Henry H. [1 ,2 ,3 ]
Khanani, Hadia [2 ]
Thompson, Nadine J. [4 ]
Sorensen, Brian J. [4 ]
Baskaranathan, Sris [2 ,3 ]
Bergersen, Philip [2 ,3 ]
Chalasani, Venu [2 ,3 ]
Dean, Thomas [2 ,3 ]
Dias, Max [2 ,3 ]
Symons, James [1 ,2 ,3 ]
Wines, Michael [2 ,3 ]
Jain, Anika [2 ]
Nassour, Anthony -Joe [2 ]
Tarlinton, Lisa C. [2 ,4 ,5 ]
机构
[1] Australian Natl Univ, Coll Hlth & Med, Canberra, Australia
[2] Sydney Adventist Hosp, SAN Prostate Ctr Excellence, Sydney, NSW, Australia
[3] Sydney Adventist Hosp, Dept Urol, Sydney, NSW, Australia
[4] Sydney Adventist Hosp, SAN Radiol & Nucl Med, Sydney, NSW, Australia
[5] Sydney Adventist Hosp, SAN Radiol & Nucl Med, 185 Fox Rd, Wahroonga, NSW 2076, Australia
来源
关键词
Magnetic resonance imaging; Positron emission tomography; Prostate biopsy; Prostate cancer; Prostate -specific membrane; antigen; DIAGNOSTIC CERTAINTY; LEXICON;
D O I
10.1016/j.euros.2022.11.012
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Prostate-specific membrane antigen (PSMA) positron emission tomography/computerised tomography (PET/CT) is increasingly being utilised in the diagnostic pathway for prostate cancer (PCa). Recent publications have sug-gested that this might help identify those who can avoid biopsy.Objective: The primary objective of this study was to determine whether PET mag-netic resonance imaging (MRI) fusion could negate the need to biopsy prior to prostatectomy in a selected population of men.Design, setting, and participant: Multiparametric MRI (mpMRI) for PCa is our stan-dard of care prior to prostate biopsy. Biopsy-naive men with one or more Prostate Imaging Reporting and Data System (PI-RADS) 4 or 5 lesions >10 mm on mpMRI were invited to undergo PSMA PET/CT prior to biopsy. Following ethics approval, 60 men were recruited between September 2020 and March 2021. The key exclusion criteria included a previous history of PCa and previous prostate sur-gery or biopsy.Outcome measurements and statistical analysis: A positive PET MRI fusion scan was defined as "consistent with"as per the Memorial Sloan Kettering Cancer Center lexicon of certainty, and concordance with biopsy results was analysed. Clinically significant PCa (csPCa) was defined as grade group (GG) >= 2 on pathology. A chi-square analysis was performed with statistical significance defined at p < 0.05.Results and limitations: A total of 71 mpMRI lesions were positive on 61 (86%) PET MRI fusion scans. Fifty-nine of 61 lesions biopsied confirmed csPCa in 54 (92%). Of five of 59 lesions for which either biopsy was negative or low-grade cancer was found, three had rebiopsy of which two were confirmed to have csPCa corroborating with PET MRI fusion and one was reconfirmed to have GG1 only. For the remaining two, both had another lesion elsewhere in the gland confirming csPCa, and hence rebiopsy was not performed. Ultimately, 56 of 59 (95%) lesions with a positive PET MRI fusion scan were confirmed to have csPCa. All GG >3 can-cers had a positive PET MRI fusion scan. Conclusions: This prospective study of PET MRI fusion assessment of men with PI-RADS 4 or 5 lesion >10 mm on mpMRI confirms that the majority of men (95%) with a positive PET MRI fusion scan will have csPCa. This supports recently pub-lished retrospective data suggesting that selected men might avoid prostate biopsy prior to radical prostatectomy.Patient summary: In this research, we have confirmed that prostate-specific mem-brane antigen positron emission tomography/computerised tomography in combi-nation with magnetic resonance imaging could have an important role in enabling a diagnosis of prostate cancer. Using the combination of these scans, we could con-fidently predict the presence of aggressive prostate cancer in some men for which treatment is warranted. This means that there are some men who could possibility proceed directly to having prostate cancer surgery without the need for a confirma-tory prostate biopsy.(c) 2022 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (http://creative-commons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:119 / 125
页数:7
相关论文
共 50 条
  • [41] An Unusual Solitary Prostate Cancer Metastasis Detected by Gallium-68 Prostate-specific Membrane Antigen-labeled Positron Emission Tomography/Magnetic Resonance Imaging
    Cetin, Serhat
    Aydos, Uguray
    Alkibay, Rafet Turgut
    Atay, Lutfiye Ozlem
    Sozen, Tevfik Sinan
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2022, 21 (01): : 32 - 34
  • [42] Prostate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine
    Bouchelouche, Kirsten
    Choyke, Peter L.
    CURRENT OPINION IN ONCOLOGY, 2016, 28 (03) : 216 - 221
  • [43] Systematic Review and Metanalysis on the Role of Prostate-Specific Membrane Antigen Positron Emission Tomography/Magnetic Resonance Imaging for Intraprostatic Tumour Assessment
    Mapelli, Paola
    Ghezzo, Samuele
    Spataro, Alessandro
    Bezzi, Carolina
    Gajate, Ana Maria Samanes
    Chiti, Arturo
    Picchio, Maria
    MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA, 2023, 31 (04) : 605 - 611
  • [44] A machine learning model incorporating 18F-prostate-specific membrane antigen-1007 positron emission tomography/computed tomography and multiparametric magnetic resonance imaging for predicting prostate-specific antigen persistence in patients with prostate cancer after radical prostatectomy
    Chen, Fangansheng
    Jiang, Jia
    Peng, Yushi
    Wang, Ling
    Lan, Junping
    Bian, Shuying
    Wang, Hanzhe
    Xiao, Zhe
    Chen, Yimin
    Fu, Yinuo
    Zheng, Xiangwu
    Tang, Kun
    QUANTITATIVE IMAGING IN MEDICINE AND SURGERY, 2025, 15 (01)
  • [45] WHICH PROSTATE CANCERS ARE UNDETECTED BY MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING IN MEN WITH PRIOR PROSTATE BIOPSY? AN ANALYSIS FROM THE PICTURE STUDY
    Norris, Joseph
    Simmons, Lucy
    Kanthabalan, Abi
    Freeman, Alex
    McCartan, Neil
    Moore, Caroline
    Punwani, Shonit
    Whitaker, Hayley
    Emberton, Mark
    Ahmed, Hashim
    JOURNAL OF UROLOGY, 2021, 206 : E464 - E465
  • [46] Editorial Comment to Positron emission tomography/magnetic resonance imaging with 68Gallium-labeled ligand of prostate-specific membrane antigen: Promising novel option in prostate cancer imaging?
    Wetter, Axel
    INTERNATIONAL JOURNAL OF UROLOGY, 2014, 21 (12) : 1288 - 1288
  • [47] Fluorine-18 Prostate-specific Membrane Antigen-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Diagnostics of Local Recurrence in a Prostate Cancer Patient After Recent Radical Prostatectomy
    Paddubny, Kiryl
    Freitag, Martin T.
    Kratochwil, Clemens
    Koerber, Stefan
    Radtke, Jan P.
    Sakovich, Ruslan
    Kopka, Klaus
    Giesel, Frederik L.
    CLINICAL GENITOURINARY CANCER, 2018, 16 (02) : 103 - 105
  • [48] Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Locally Advanced, Recurrent, and Metastatic Prostate Cancer
    Perera, Marlon
    Murphy, Declan
    Lawrentschuk, Nathan
    JAMA ONCOLOGY, 2018, 4 (05) : 748 - +
  • [49] Comparison of Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging in Patients with Prostate Biopsy Indications
    Altay, Mehmet Sefa
    Ozkaya, Fatih
    Demirdogen, Saban Oguz
    Bedir, Fevzi
    Kocaturk, Huseyin
    Cinislioglu, Ahmet Emre
    Yilmaz, Sinan
    Yapanoglu, Turgut
    EURASIAN JOURNAL OF MEDICINE, 2022, 54 (01): : 12 - 16
  • [50] Prostate-specific Membrane Antigen Positron Emission Tomography-guided Radiotherapy
    Kishan, Amar U.
    Nickols, Nicholas G.
    Spratt, Daniel E.
    EUROPEAN UROLOGY FOCUS, 2021, 7 (02): : 250 - 253